Media Release

Bachem Annual General Meeting 2024

• All proposals of the Board of Directors approved.
• Dividend of CHF 0.80 per share.

Bachem Holding AG (“Bachem”, SIX: BANB) announced today that its Annual General Meeting 2024 has approved all proposals of the Board of Directors. A total of 84.45% of the 74‘981‘645 eligible shares were present.

The Annual General Meeting approved a dividend of CHF 0.80 per share. The dividend will be paid on April 30, 2024. The last trading day entitling to receive the dividend is April 25, 2024. As of April 26, 2024, the shares will be traded ex-dividend.

Both the Chairman and the other members of the Board of Directors were re-elected for a further year. The existing members of the Compensation Committee were also re-elected for a further year.

The shareholders approved the annual report, the financial statements of Bachem Holding AG, the consolidated financial statements for the business year 2023, as well as the appropriation of retained earnings and reserves from capital contributions and the total amount of the annual compensation paid to the Board of Directors and to the Corporate Executive Committee. Further, the shareholders approved the sustainability report and, in a consultative vote, the remuneration report.

MAZARS SA, Zurich was appointed by the Annual General Meeting as auditor of Bachem Holding AG for the business year 2024.

A detailed list of all resolutions will be made available at  https://www.bachem.com/about-bachem/investors-and-media/financial-events/.

Financial calendar
April 30, 2024             Payout date for dividend
July 25, 2024              Publication of Half-Year Report 2024
February 27, 2025      Publication of Annual Report 2024; Media and Analyst conference
April 30, 2025             Annual General Meeting (business year 2024)

About Bachem
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has over 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange. For further information, see www.bachem.com .

For more information: 

Bachem Holding AG
Dr. Daniel Grotzky
Head Group Communications
Tel.: +41 58 595 2021  

Media: media@bachem.com
Investors: ir@bachem.com